Open AccessLong-term results of cornea collagen cross-linking with riboflavin for keratoconus
Author(s) -
Vinay Agrawal
Publication year - 2013
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/0301-4738.116072
Subject(s) - keratoconus , medicine , coma (optics) , visual acuity , riboflavin , ophthalmology , corneal collagen cross linking , cornea , optics , biology , biochemistry , physics
Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.